Company intelligence / Profile preview

Aro Biotherapeutics

Philadelphia, Pennsylvania, United Statesarobiotx.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

ABX1100, their lead program for LOPD, has shown promising results in Phase 1 trials with normal healthy volunteers, demonstrating approximately 70% knockdown of GYS1 mRNA and protein at 10 weeks following two doses. The company has dosed the first patient in a Phase 1b trial for LOPD in January 2025 and received FDA clearance of the IND application in February 2025.

Therapeutic areas: OncologyImmunologyRare Diseases
Modalities: Centyrin-siRNA conjugatesCentyrin-based therapeutics
Industry: Biotech

Drug pipeline

6 assets

ABX1100

5 more assets in the full pipeline.

Request access →

Partnerships

Industry partners leveraging Centyrins for tissue-specific targeting of therapeutics

Beyond the preview

Go deeper on Aro Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aro Biotherapeutics.

Explore the full profile